he rapid detection and/or identification (ID) of the microbial pathogens responsible for bloodstream infections (BSIs) is pivotal for reducing infection-related mortality and costs (1), particularly for severely ill patients (2, 3). Although blood culture (BC) continues to be essential for BSI diagnosis, the turnaround time for ID can be accelerated using new technologies that are directly applied to positive BC bottles/broths (4).
T
he rapid detection and/or identification (ID) of the microbial pathogens responsible for bloodstream infections (BSIs) is pivotal for reducing infection-related mortality and costs (1), particularly for severely ill patients (2, 3) . Although blood culture (BC) continues to be essential for BSI diagnosis, the turnaround time for ID can be accelerated using new technologies that are directly applied to positive BC bottles/broths (4) .
Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) was recently demonstrated to improve the clinical management of BSIs (5, 6) and allow patients to receive appropriate antimicrobial therapy earlier (i.e., 24 h from the first positive BC) (7) . However, despite its well-documented good performance (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) , this method often fails to identify polymicrobial BCs in their entirety.
Another method is the multiplex PCR-based FilmArray blood culture ID (BCID) panel (bioMérieux, Marcy l'Etoile, France), which is equally as fast as the MALDI-TOF MS (e.g., MALDI BioTyper system [Bruker Daltonics, Bremen, Germany]). This technique was developed for the simultaneous identification of 24 microbial pathogens, including 19 bacterial genera/species and 5 Candida species (and 3 antibiotic resistance determinants). In addition to its high sensitivity and specificity, the FilmArray BCID panel has proven to be accurate for identifying not only monomicrobial but also polymicrobial BCs (18) (19) (20) (21) (22) (23) . Notably, successful results were obtained with BC broths tested before the bottles became positive or even before the bottles were incubated in the BC instrument as usual (24) . To date, the extensive use of the FilmArray BCID panel in routine clinical laboratory practice has been hampered by the high cost of reagents/consumables.
In this study, we developed a BSI diagnostic algorithm that relied on the direct analysis of positive BC bottles/broths using the MALDI BioTyper system supplemented with the FilmArray BCID panel. We evaluated this algorithm in terms of ID accuracy and turnaround time by comparing the results with a reference culture-based procedure.
(This work has been presented in part as a poster at the 24th European Congress of Clinical Microbiology and Infectious Diseases, 10 to 13 May 2014, Barcelona, Spain).
MATERIALS AND METHODS
Setting, design, and samples. The study was conducted prospectively between December 2013 and April 2015 at the Catholic University of the Sacred Heart Medical Center, which is a large tertiary-care hospital in Rome, Italy. The hospital is entirely served by our clinical microbiology laboratory, which diagnoses an average of 90 BSI episodes per month. Blood samples were inoculated in aerobic and anaerobic Bactec bottles (Becton Dickinson Instrument Systems, Sparks, MD, USA) and incubated at 35°C until they yielded a positive signal or for up to 5 days in a BD Bactec FX automated instrument. Positive BC bottles were submitted for conventional (i.e., Gram stain analysis and culture-based ID) and direct (i.e., MALDI BioTyper system and/or FilmArray BCID panel) tests, according to the BSI diagnostic algorithm described in this study (Fig. 1) . Direct MALDI BioTyper testing was performed on BC broths following Gram stain analysis and the report of the results to the treating physician when a single morphology was noted. Conversely, FilmArray BCID testing was performed on BC broths when multiple morphologies were noted and when the MALDI BioTyper analysis failed to provide reliable results (i.e., identifications with scores of Ͻ1.8, multiple hits in the top 10 matches list with scores of Ͼ1.7 and Ͻ1.8 that were suggestive of the presence of Ͼ1 microbial species, or the identification of organisms, such as Streptococcus pneumoniae). Only one positive (aerobic) BC bottle per patient episode was used for the direct assays. The direct assays were performed several times daily on weekdays (from 7:30 a.m. to 7:00 p.m., Monday through Saturday). Blood cultures that arrived when the laboratory was closed were stored at room temperature, as previously described (15) . All consecutive positive BC bottles representing clinically significant BSI episodes (defined a posteriori as the isolation of bacteria and/or yeasts from the blood in the presence of signs and/or symptoms of infection and/or the isolation of at least one organism that was considered clinically relevant by the treating physician with the support of an infectious disease consultant [25, 26] ) were included in the final evaluation of our MALDI BioTyper/FilmArray BCID panel-based diagnostic algorithm. Cultures growing commensal organisms, such as coagulase-negative staphylococcus (CoNS) and viridans streptococcus, were judged to be clinically relevant when these organisms were recovered from Ͼ2 BCs in patients with clinical manifestations of infection that were not explained by other causes (15) . BSI episodes separated by Ͼ1 week were considered to represent different episodes per patient.
Culture-based reference ID and susceptibility testing. Aliquots from each positive BC bottle/broth were subjected to routine Gram staining microscopy and solid-medium subcultures. After isolation from the cultures, bacteria and yeasts were identified by MALDI BioTyper analysis; in cases in which the isolate could not be identified (i.e., ID score was Ͻ2.0), conventional phenotypical tests and/or sequencing of the 16S rRNA gene or the rpoB gene (for bacterial isolates) and the internal transcribed spacer 1 (ITS1)-5.8S-ITS2 rRNA gene region (for fungal isolates) were performed as previously described (11, 15, 27) . Antimicrobial susceptibility testing of the bacterial isolates was performed as part of the routine BC analyses with the Vitek 2 (bioMérieux) and/or Etest (bioMérieux), and interpreted according to EUCAST guidelines. Additionally, PCR amplification and sequencing analyses were performed to confirm the presence of the bla KPC (for Klebsiella pneumoniae), mecA (for staphylococci), or vanA or vanB (for enterococci) genes obtained with the FilmArray BCID panel assays (see below).
MALDI BioTyper system ID. MALDI-TOF MS assays were performed starting from 8-ml BC aliquots, as previously described (11, 15) . Briefly, pellets containing bacterial or yeast cells were washed and then suspended in distilled water plus absolute ethanol. After centrifugation, each microbial pellet was extracted by adding 70% formic acid plus pure acetonitrile, and 1 l of the final supernatant was spotted in duplicate onto a polished steel MALDI target plate (Bruker Daltonics). The spots from each sample were overlaid with 1 l of matrix solution (␣-cyano-4- (reference) microbial identification methods on positive blood culture (BC) broths. According to the developed algorithm, the FilmArray BCID panel assays were performed on BC broths that revealed multiple morphologies by Gram staining and in all cases for which MALDI BioTyper analysis failed to provide reliable results (i.e., identifications with scores of Ͻ1.8, multiple hits in the top 10 matches list with scores ranging from Ͼ1.7 to Ͻ1.8 that were suggestive of the presence of Ͼ1 microbial species, and identifications of organisms, such as S. pneumoniae). MALDI-TOF MS, matrix-assisted laser desorption ionization-time of flight mass spectrometry; BCID, blood culture identification.
hydroxycinnamic acid in 50% acetonitrile-2.5% trifluoroacetic acid) and allowed to dry. MALDI-TOF mass spectra were acquired using a Microflex LT benchtop mass spectrometer (Bruker Daltonics). The MALDI BioTyper 3.1 software (Bruker Daltonics) was used for spectra analysis and comparison with the reference database (updated with 6,270 species). Each database query returned the top 10 identification matches along with scores ranging from 0.0 to 3.0; the match with highest score was used for species identification. Scores of Ն1.8 were considered valid for specieslevel ID (14, 28) , and samples with a score ranging of Ͼ1.7 and Ͻ1.8 were repeated once. Scores of Ͻ1.7 were considered an unreliable ID, according to the manufacturer's recommendations.
FilmArray and the 3 previously mentioned antibacterial resistance determinants, according to the manufacturer's instructions. Briefly, a 100-l BC aliquot was diluted in the FilmArray dilution buffer. The diluted sample (300 l) was injected into the prehydrated FilmArray pouch before loading it into the FilmArray system for the automated analysis steps (i.e., DNA isolation, amplification, and detection/identification). Two internal run controls were included for both the amplification and detection steps. The results were automatically provided by the software based on the post-PCR DNA melting curve data if the quality control reaction mixtures were appropriately detected. When either of the two controls failed, the result was listed as invalid. All samples with invalid or negative results were repeated once.
Data analysis. Overall, the ID results were assessed at the following levels of comparison: (i) combined use of the MALDI BioTyper system and FilmArray BCID panel versus the reference method, (ii) the MALDI BioTyper system versus the reference method, and (iii) the FilmArray BCID panel versus the reference method. For each comparison, the results were classified as follows: correct, both (test and reference) methods provided the same ID at the species level; incorrect, both methods provided an organism ID that did not match at the species level; and no result, the MALDI BioTyper system and/or FilmArray BCID panel did not provide a reliable or valid ID result. The results of the FilmArray BCID panel were considered correct if the species identified with the reference method was included in the genus/species group that the BCID assay was designed to detect. For each method, concordance with the reference ID results was calculated as the number of correct organism IDs divided by the total number of organisms identified.
For samples in which more than one pathogen was detected, the results were classified as follows: complete identification, the MALDI BioTyper system or FilmArray BCID panel detected all pathogens identified by the reference method; and incomplete identification, at least one of the pathogens identified by the reference method was not detected by the MALDI BioTyper system or FilmArray BCID panel. The data are presented as numbers (%) or medians (interquartile range [IQR]), as appropriate. To assess the differences between the study methods, the median TFIs were compared using the Wilcoxon matchedpairs signed-rank test. A P value of Յ0.05 was considered statistically significant. The statistical analyses were performed with Stata version 11.1 (StataCorp, College Station, TX, USA).
RESULTS
During the study period, we evaluated 1,394 consecutive BSI episodes, of which 1,223 (87.7%) were monomicrobial infections and 171 (12.3%) were polymicrobial infections. Of the polymicrobial episodes, 154 episodes were caused by two organisms, and 17 episodes were caused by at least three organisms (only 3 grew 4 organisms). Among all of the BSIs, 658 (47.2%) BSIs were due to Gram-negative bacteria only, 511 (36.7%) BSIs were due to Grampositive bacteria only, 116 (8.3%) BSIs were due to yeasts, 80 (5.7%) BSIs were due to both Gram-negative and Gram-positive bacteria, and 29 (2.1%) BSIs were due to both Gram-negative or Gram-positive bacteria and yeasts. A total of 1,585 organisms were isolated, of which 788 (49.7%, 164 from polymicrobial BCs) organisms were Gram-negative bacteria, 651 (41.1%, 168 from polymicrobial BCs) organisms were Gram-positive bacteria, and 146 (9.2%, 30 from polymicrobial BCs) organisms were yeasts.
Results of combined MALDI BioTyper and FilmArray BCID panel. (i) Overall results. Of the 1,394 BSI episodes studied, the causative organisms of 97.7% (1,362 BSIs, including 153 polymicrobial episodes) were correctly identified by our MALDI BioTyper and FilmArray BCID-based algorithm ( Fig. 1) , with accuracy rates ranging from 88.8% for mixed Gram-negative/ Gram-positive bacterial episodes to 98.5% for Gram-negative bacterial episodes. Specifically, the MALDI BioTyper system allowed for the identification of the causative organisms of 82.1% of the BSIs (1,144/1,394 of all monomicrobial episodes), and the FilmArray BCID panel allowed for the identification of the causative organisms of another 15.6% of the BSIs (218/1,394, including 65 mono-and 153 polymicrobial episodes). Of the 32 remaining BSIs (2.3%), 17 (all polymicrobial episodes) did not yield a complete ID result, and 15 (14 mono-and 1 polymicrobial episodes) did not yield a correct or valid ID result compared to the reference culture-based method.
Of the total BSI organisms, 97.9% (1,552/1,585) were correctly identified by our MALDI BioTyper and FilmArray BCID panelbased algorithm (Tables 1 and 2 ), with ID rates of 97.4% (634/ 651) for Gram-positive bacteria, 98.2% (774/788) for Gram-negative bacteria, and 98.6% (144/146) for yeasts. Of the 33 remaining microorganisms (2.1%, 19 were from polymicrobial cultures), 31 microorganisms failed to be detected, and 2 microorganisms were not correctly identified (1 Enterococcus faecium as Enterococcus faecalis and 1 Staphylococcus capitis as Staphylococcus epidermidis). Twenty-six of the 31 microorganisms were species/ genera that the FilmArray BCID panel was not designed to detect (Tables 1 and 2 ). Four additional organisms were detected by the FilmArray BCID panel but not by the BCs; of them, 2 (1 Enterococcus sp. and 1 C. albicans) were detected in 2 BCs that grew E. coli and S. epidermidis (not shown), and 2 (both CoNS organisms) were detected in 2 BCs with otherwise-detected polymicrobial growth (see Table S1 in the supplemental material).
(ii) Monomicrobial cultures. The MALDI BioTyper system identified 1,144 (93.5%) out of 1,223 isolates recovered from monomicrobial cultures, including 605 (96.9%) out of 624 Gramnegative bacteria, 105 (90.5%) out of 116 yeasts, and 434 (89.9%) out of 483 Gram-positive bacteria (Table 1) . Additionally, the FilmArray BCID panel identified 65 (5.3%) isolates that were initially tested but not identified with the MALDI BioTyper system. As shown, all 10 isolates of S. pneumoniae (9 of which were iden- (Table 2 ). In 31 of the 171 polymicrobial episodes, BCs were not directly processed with the FilmArray BCID panel, because different Gram stain morphologies were not observed (Fig. 1) . However, the MALDI BioTyper results indicated no reliable ID (15 episodes) or suggested the presence of more than one species (16 episodes).
As detailed in Table S1 in the supplemental material, the FilmArray BCID panel provided incomplete ID results for all of the polymicrobial assortments of BCs tested, including Gramnegative bacteria alone (n ϭ 5; 34 BCs tested), Gram-positive bacteria alone (n ϭ 3; 28 BCs tested), Gram-negative and Grampositive bacteria (n ϭ 8; 80 BCs tested), or bacteria (Gram-negative/Gram-positive) and yeasts (n ϭ 1; 29 BCs tested). In the last group, an incomplete ID was reported for only 1 BC that included Staphylococcus hominis (mecA positive), C. albicans, and Stenotrophomonas maltophilia, with the last organism giving an expected negative result (the species was not detectable by the FilmArray BCID panel).
The 362 polymicrobial BC broths were also tested with the MALDI BioTyper (see Table S1 in the supplemental material 
DISCUSSION
To the best of our knowledge, this study represents the first largescale clinical evaluation of the use of the MALDI BioTyper system coupled to the FilmArray BCID panel for the direct detection/ identification of the causative organism of BSIs from positive BCs. Through integrated testing with both methods, our diagnostic algorithm allowed the successful identification of ϳ98% of the BSI-causing organisms studied and more importantly potentiated the utility of each method individually. This approach resulted in 65/1,223 (5.3%) monomicrobial cultures whose organisms could not be correctly detected or that failed to be identified with the MALDI BioTyper system but were accurately identified with the FilmArray BCID panel; a total of 9 of the 65 microorganisms were Candida yeasts. Furthermore, 153/171 (89.5%) polymicrobial cultures contained organisms that were identified in their completeness (although at least one of the microorganisms present in these cultures was identified by the FilmArray BCID panel). Conversely, the full use of the MALDI BioTyper system (i.e., use of the method not on the basis of the initial [Gram-stain driven] discrimination between BCs with mono-or polymicrobial growth) would have resulted in the identification of only 1 causative organism in 97/171 (56.7%) of the polymicrobial cultures. Exceptionally, the second causative organism would have been identified in 3/171 (1.7%) of the polymicrobial cultures (1 E. coli ϩ 1 K. pneumoniae, 1 E. coli ϩ 1 S. epidermidis, and 1 K. pneumoniae ϩ 1 S. epidermidis); in 1 additional polymicrobial culture (1 E. coli ϩ 1 E. faecalis ϩ 1 E. faecium), only E. faecium would have been identified out of the two enterococcal species present in the BC broth (see Table S1 in the supplemental material).
In theory, MALDI-TOF MS is capable of identifying a wide range of pathogens in broths from BC bottles. However, the method requires manual processing, such as centrifugation or filtration concentration, prior to analysis, and the MALDI-TOF MS procedures for BC are still being standardized (13, 29, 30) . Low microbial loads, especially low fungal loads (Ͻ10 4 CFU/ml), can be a relevant cause of ineffective direct ID using the MALDI BioTyper system (11, 28) . Taking advantage of our consolidated experience with this method (11, 15) , we used a starting volume of 8 ml instead of the 1.5 ml used elsewhere (28) for each of the positive BC broths subjected to multiple preanalytical treatments (including the centrifugation and washing steps). Therefore, we noted that the direct MALDI BioTyper method had a high performance Rand et al. (22) , the slight superiority of the FilmArray BCID panel over the MALDI-TOF MS system (Vitek MS; bioMérieux) was demonstrated for 151 monomicrobial BC bottles, although the authors excluded 18 monomicrobial organisms that were not identified, as expected from the manufacturer's database. Interestingly, the FilmArray BCID panel identified 20/21 (95.2%) organisms, in contrast to the 1 organism identified with the Vitek MS system from 7/10 (70.0%) polymicrobial cultures analyzed in that study (22) .
One strength of our study is that the cultures with polymicrobial growth accounted for a relatively large percentage of BCs (171/1,394 BCs [12.3%] ). Testing these cultures (which were ϳ7-to 17-fold higher in number than those tested elsewhere [19, 22] ) allowed us not only to confirm and strengthen the usefulness of the FilmArray BCID panel for the diagnosis of BSI but also to establish the validity of a clinical laboratory diagnostic strategy that applied the FilmArray BCID assay to selected clinical specimens/situations. The method has several advantages; for instance, it contains antibiotic resistance determinants that make the FilmArray BCID panel particularly useful in cases of BSI due to organisms, such as S. aureus and Enterococcus spp., for which the rapid detection of the mecA and vanA or vanB genes might impact therapeutic decisions. Nonetheless, based on our diagnostic algorithm, we did not triage all of the BCs with monomicrobial growth for S. aureus or Enterococcus identified by the MALDI BioTyper for antimicrobial resistance testing. However, clinical microbiology laboratories, such as ours, are equipped with molecular assay alternatives to the FilmArray BCID panel that allow rapid (and more inexpensive) testing at least for methicillin resistance in S. aureus organisms. After the initial investment, excessive costs (pricing for the FilmArray is in the range of €150 to 159/test) might arise through integral (not circumstantiated) use of the FilmArray BCID panel. The estimated cost savings with our diagnostic strategy, which minimizes the use of FilmArray BCID panel (218 BCs tested versus 1,394 testable BCs) is €176,480. In contrast, full use of the MALDI BioTyper (1,394 BCs tested) would have resulted in an overall reagent/consumable expenditure of €4,042.6 (€2.9/sample). However, this difference is not so remarkable if we consider the technologist time/labor involved with the MALDI BioTyper processing, which is considerably higher than that of the FilmArray BCID panel, because this assay requires only 3 min of hands-on processing and approximately 1 h of instrument time for an individual test.
Despite differing hands-on time requirements, as expected, both methods (alone or in combination) led to a significantly shortened TFI by 22.2 h compared with routine (conventional) methods. Due to the design of our study, we did not include an analysis of patient outcomes. However, it is plausible that a rapid and precise ID to the species level and a rapid differentiation between more virulent organisms (S. aureus versus L. monocytogenes) or between organisms with predictable antimicrobial resistance (Enterobacter spp. versus K. pneumoniae) may have helped our physicians in the clinical and/or therapeutic management of BSI patients. Additional studies will be necessary to clearly establish the clinical impact of our diagnostic strategy, particularly in light of the evidence that performing rapid ID for patients with positive BCs does not affect antimicrobial therapies without resistance genotyping and/or clinical intervention (31) . However, the implementation of such an algorithm would imply that some positive BCs are unnecessarily subjected to the MALDI BioTyper/ FilmArray BCID panel testing in daily clinical laboratory practice because they would be judged to be clinically significant only a posteriori.
One limitation of our study is the lack of or insufficient testing of certain pathogens. For example, both methods can detect N. meningitidis, but no culture grew this microorganism; other pathogens, such as H. influenzae, Burkholderia cepacia, Clostridium septicum, and Rhodotorula mucilaginosa, were tested only once. The list of microorganisms included in the FilmArray BCID panel may encompass almost 95% of the organisms commonly found in positive BCs; however, 26/31 (83.9%) ID failures in our study were due to organisms that were undetectable by the method. Future improvements might allow the spectrum of microbial targets detected by the FilmArray BCID panel to be enlarged. However, at the time of this writing, subculture was indispensable for a small number of BSI episodes, and the growth of colonies was needed to perform susceptibility testing for all BSI episodes. Another drawback of the FilmArray BCID panel is the rate of false-positive results (especially false-positive Enterococcus species results) that occurs despite a product recently optimized by the manufacturer to improve sample specificity. This optimization was designed to mitigate the cross-reactivity of the Enterococcus assay with Staphylococcus organisms (heavy growth of CoNS was noted to cause this effect [31] ) and was shown to have a positive impact on the FilmArray BCID panel performance (32) .
In conclusion, we demonstrated the reliability of a rapid, accurate, and cost-effective approach for the direct ID of the microorganisms most commonly isolated from BCs. We used two innovative methods (the FilmArray BCID panel and MALDI BioTyper system) with differing but excellent performances to achieve fast and efficient BC testing for the clinical microbiology laboratory. Whether this approach can be an important and useful tool for the management of BSI remains to be established in the future.
